First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. Journal Abstract

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.

Publication Date: 2024 Aug 13

Full Text Sources

Authors

Georgina V Long; Evan J Lipson; F Stephen Hodi; Paolo A Ascierto; James Larkin; Christopher Lao; Jean-Jacques Grob; Flavia Ejzykowicz; Andriy Moshyk; Viviana Garcia-Horton; Zheng-Yi Zhou; Yiqiao Xin; Jennell Palaia; Laura McDonald; Sarah Keidel; Anthony Salvatore; Divya Patel; Leon A Sakkal; Hussein Tawbi; Dirk Schadendorf

Abstract

OBJECTIVE

Nivolumab plus relatlimab and nivolumab plus ipilimumab have been approved for advanced melanoma on the basis of the phase II/III RELATIVITY-047 and phase III CheckMate 067 trials, respectively. As no head-to-head trial comparing these regimens exists, an indirect treatment comparison was conducted using patient-level data from each trial.

Source

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Pub Types(s)

Journal Article

Language

English

PubMed ID

39137386